The present disclosure is directed to a composition comprising micronized cromolyn sodium, α-lactose, and a salt of fatty acid, wherein the α-lactose has a particle size distribution of D90 of 45-70 μm, D50 of 10-35 μm, and D10 of 2-13 μm. The present disclosure is also directed to a method of treating Alzheimer's disease, amyloidosis-associated condition (AAC), traumatic brain injury, Huntington's disease, atherosclerosis, cytokine release syndrome (CRS), dementia, head injury, infection, neuroinflammation, prion disease, stroke, amyotrophic lateral sclerosis (ALS), Parkinson's disease, or asthma using the composition.